AL-LAD, or ALLAD, also known as ALLY-LAD or as 6-allyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).
The drug interacts with serotonin and dopamine receptors and is known to act as an agonist of the serotonin 5-HT2A receptor similarly to LSD.
AL-LAD was first described in the scientific literature by 1976.
Use and effects
In his book
TiHKAL (
Tryptamines I Have Known and Loved), Alexander Shulgin describes the dose range of AL-LAD as 80 to 160μg and its duration as 6 to 8hours.
In other publications however, Shulgin listed its dose range as 50 to 150μg.
A typical or moderate dose may be around 100μg.
The drug appears to be roughly
equipotent with
LSD, which has a listed dose range of 50 to 200μg.
AL-LAD's duration appears to be shorter than that of LSD, which is said to have a duration of 8 to 12hours.
The onset of AL-LAD has been reported to be within 15 to 20minutes, but others reported a slower and more gradual onset building up over a few hours.
It has also been reported to have a very long "down-ramp" of effects.
AL-LAD has been described as producing similar effects to LSD and as being "really trippy" similarly, but to lack the "vaguely sinister push" of LSD.
Interactions
Pharmacology
Pharmacodynamics
AL-LAD has been found to interact with the
serotonin 5-HT
1 and 5-HT
2 receptors and with the
dopamine D
1 and D
2 receptors.
It is known to act as a potent
full agonist of the
serotonin 5-HT
2A receptor.
The drug was about 3.5-fold more potent than LSD in substituting for LSD in drug discrimination tests in rodents.
Pharmacokinetics
The
in-vitro drug metabolism of AL-LAD has been studied.
Chemistry
AL-LAD, also known as 6-allyl-6-nor-LSD or as 6-allyl-6-nor-
N,
N-diethyllysergamide, is a synthetic substituted lysergamide and a 6-substituted derivative of
nor-LSD (LAD).
Detection
AL-LAD does not cause a color change with the
Marquis reagent,
Mecke reagent or
Mandelin reagent reagents,
but does cause the Ehrlich's reagent to turn purple because of the presence of the
indole moiety in its structure.
Synthesis
The chemical synthesis of AL-LAD has been described.
It is starting from
nor-LSD as a precursor, using
allyl bromide as a reactant.
Analogues
AL-LAD is closely related to other 6-substituted lysergamides such as
LSD (METH-LAD),
ETH-LAD,
PRO-LAD, and
MAL-LAD, among others.
of AL-LAD include 1P-AL-LAD, 1cP-AL-LAD, and 1T-AL-LAD.
History
AL-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues in 1976.
Subsequently, it was further studied by Andrew J. Hoffman and David E. Nichols in 1985.
Alexander Shulgin described the effects of AL-LAD in humans in his 1997 book
TiHKAL (
Tryptamines I Have Known and Loved).
The drug was encountered as a novel
designer drug in
Europe by 2015.
Society and culture
Legal status
International
AL-LAD is not scheduled by the
United Nations' Convention on Psychotropic Substances overcome is legal ever that doesn't be sold for recreational usage, could be sold for medical or research purposes like a research chemical..
Denmark
AL-LAD is illegal in Denmark.
Finland
Listed in a decree of the government's psychoactive substances banned from the consumer market.
France
AL-LAD is illegal in France.
Latvia
AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analogue due to an amendment made on June 1, 2015.
Sweden
Riksdag added AL-LAD to
Narcotic Drugs Punishments Act under
Swedish schedule I (
"substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation
HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.
Switzerland
AL-LAD is illegal in Switzerland.
United Kingdom
AL-LAD is illegal in the UK. On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use.
The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
United States
AL-LAD is a Controlled Substance at the federal level in the
United States,
AL-LAD could be legally considered an analogue of the Schedule I drug
LSD, therefore, sales, possession or consumption for recreational not medical nor scientific use could be prosecuted under the Federal Analogue Act.
See also
External links
target="_blank" rel="nofollow"> AL-LAD - UK Chemical Research
